Antiangiogenic therapy in the management of brain tumors: a clinical overview Saroj KunnakkatMaya MathewAshwatha Narayana Review Article 24 July 2012 Pages: 353 - 363
Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer Li HanYa Feng WangQing Duan Wang Original Article 11 July 2012 Pages: 365 - 372
Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment Yumiko AoyamaTetsuya NishimuraKazuhiko Nakagawa Original Article Open access 18 July 2012 Pages: 373 - 380
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer Jae-Sung KimJoo Han LimYong Bum Yoon Original Article 18 July 2012 Pages: 381 - 389
Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis Yuki KojimaKenji HashimotoYasuhiro Fujiwara Original Article 18 July 2012 Pages: 391 - 397
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer Yosuke TogashiKatsuhiro MasagoMichiaki Mishima Original Article 18 July 2012 Pages: 399 - 405
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors Haruyasu MurakamiToshihiko DoiElwyn Loh Original Article Open access 19 July 2012 Pages: 407 - 414
Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human prostate cancer cells through induction of actin aggregation and cofilin-actin rod formation Shuai RenDong-Yun OuyangXian-Hui He Original Article 20 July 2012 Pages: 415 - 424
Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways Xiuxia LiXuewei WangLijuan Chen Original Article 20 July 2012 Pages: 425 - 437
Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates Diego A. GianolioCecile RouleauBeverly A. Teicher Original Article 22 July 2012 Pages: 439 - 449
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis Yasuyoshi MiyataKoichiro NomataHideki Sakai Original Article Open access 03 August 2012 Pages: 451 - 459
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia Mike DennisMichelle DaviesPaul Stockman Original Article Open access 04 August 2012 Pages: 461 - 469
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors Suzanne F. JonesJeffrey R. InfanteHoward A. Burris III Clinical Trial Report 01 August 2012 Pages: 471 - 475
AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts Radhika IyerCarly R. VarelaGarrett M. Brodeur Short Communication 24 May 2012 Pages: 477 - 486
Dose escalation and pharmacokinetic study of nanoparticle curcumin… by Kanai et al., CCP 69:65–70, 2012 Andreas J. Gescher Letter to the Editor 19 July 2012 Pages: 487 - 487
In response Masashi KanaiShigemi MatsumotoAtsushi Imaizumi Reply to the Letter 29 July 2012 Pages: 489 - 489
